China opens up to Aerocrine's asthma test

China opens up to Aerocrine's asthma test

SOLNA, Sweden, 27 June 2008—Aerocrine AB announced today that its handheld
airway inflammation monitor, NIOX MINO®, has been registered for marketing and
sale in China. 

Aerocrine's method of measuring airway inflammation, using exhaled nitric oxide
(NO) tests, has also been incorporated into China's national guidelines for
asthma management. Tests for airway inflammation have received a reimbursement
code.

In December last year, NIOX®, Aerocrine's larger device, was registered by the
SFDA, the Chinese equivalent of the FDA. Clearance of NIOX MINO—Aerocrine's
major product—means the company's Chinese partner Bioson Inc. can now begin
product sales for broad clinical use by Chinese physicians. 

The newly revised Chinese National Guidelines for Asthma Treatment and
Prevention state that “…exhaled nitric oxide can be used as a non-invasive
marker of airway inflammation in asthma…measuring airway inflammation is helpful
in choosing the best treatment scheme for asthmatic patients.” 

The new guidelines have resulted in a reimbursement code being designated for
Aerocrine's method to measure airway inflammation. The code is the first big
step towards doctors using NIOX MINO securing payments per test.

Anti-inflammatory therapy is a cornerstone of asthma treatment. Measuring
inflammation helps improve the diagnosis of patients with asthma-like symptoms,
to predict and measure drug response objectively and to optimize treatment
doses. By regular monitoring of airway inflammation, the management and care of
Chinese asthma patients could be dramatically improved, resulting in more
cost-effective treatment.

NIOX MINO's registration is very encouraging for Aerocrine and Bioson, and
coincides with the 6th Chinese National Congress on Asthma held in Suzhou City,
Jiangsu province, this week. China's asthma specialists are convening at the
Congress to learn more about the latest developments in asthma management.

For more information, please contact:

Tom Sundelin, Sales Director, telephone: +46 (0) 70 600 0967
Paul de Potocki, CEO, telephone: +46 (0)8 629 0782

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
09.00 am on June the 27th 2008.